SCHEMBL27248068

SCHEMBL27248068

C#CCOc1ccc2cc(CNC(=O)C3(C)CC3)[nH]c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 3/20 0.41
▸ MTNR1B P49286 1/20 0.41
▸ MAOA P21397 2/20 0.39
▸ MAOB P27338 2/20 0.39
▸ CA12 O43570 2/20 0.36
▸ CA4 P22748 2/20 0.36
▸ CA9 Q16790 2/20 0.36
▸ CA1 P00915 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ METTL3 Q86U44 4/20 0.35
▸ METTL14 Q9HCE5 4/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SNCA P37840 1/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ ACACB O00763 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30920709 0.85 MTNR1A (0.57) MTNR1AMTNR1BSMN1; SMN2RAB9AMEN1
SCHEMBL30920247 0.83 MTNR1A (0.41) MTNR1AMTNR1BSMN1; SMN2METTL3METTL14
SCHEMBL27247424 0.82 MAOB (0.49) MTNR1AMTNR1BMAOAMAOBRAB9A
SCHEMBL27247192 0.82 MAOB (0.45) MTNR1AMTNR1BMAOAMAOBSMN1; SMN2
SCHEMBL27247600 0.82 MTNR1A (0.40) MTNR1AMTNR1BMAOAMAOBSMN1; SMN2
SCHEMBL27247630 0.82 MTNR1A (0.40) MTNR1AMTNR1BSMN1; SMN2METTL3METTL14
SCHEMBL27247898 0.82 RAB9A (0.40) MTNR1AMTNR1BMAOAMAOBMETTL3
SCHEMBL27247390 0.81 METTL3 (0.39) MTNR1AMTNR1BSMN1; SMN2METTL3METTL14
SCHEMBL27248294 0.81 MAOA (0.40) MTNR1AMTNR1BMAOAMAOBMETTL3
SCHEMBL27247644 0.80 MTNR1A (0.39) MTNR1AMTNR1BMAOAMAOBMETTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601635-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2025-08-20 — — EP disclosed
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 MTNR1A 158/4885MTNR1B 111/4885MAOA 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback